For LUAD tumor cells with the ability to metastasize to the pleura and foster a malignant pleural effusion (MPE), it has been shown that the determining factor is the presence of KRAS activating mutations, which favor the production of CCL2 by the tumor cells. Here, KRAS is linked to neoplasm.